API Holdings (Pharmeasy): Financial Results for FY24

07 November 2024

• Revenue- In FY24, the company’s revenue dropped by 15%, decreasing from Rs. 6,644 cr in FY23 to Rs. 5,664 cr. This decline was primarily due to reduced sales in both trading and distribution of pharmaceutical and cosmetic goods, as well as services. However, despite the revenue fall, the company managed to reduce its net loss, which improved from Rs. -5,212 cr in FY23 to Rs. -2,534 cr in FY24. This improvement also reflected in the EPS, which increased from Rs. -9 in FY23 to Rs. -4 in FY24.
• Financial performance- The company’s overall asset base saw a modest increase of 2%, rising from Rs. 8,256 cr in FY23 to Rs. 8,390 cr in FY24. Additionally, the company’s total equity grew by 6%, moving from Rs. 2,437 cr in FY23 to Rs. 2,588 cr in FY24.